Daijiworld Media Network - Stockholm
Stockholm, Apr 12: Alligator Bioscience has announced that it is exploring options for advancing its immuno-oncology drug candidate mitazalimab into Phase 3 development for first-line metastatic pancreatic cancer.
The company said it has signed a letter of intent with Unicancer, a non-profit clinical cancer research group, to assess the feasibility of conducting a global investigator-sponsored Phase 3 study.
The collaboration is part of Alligator’s broader efforts, alongside ongoing partnering discussions, to evaluate potential pathways for late-stage clinical development of mitazalimab.
The company clarified that no final development decisions have been made so far, and the initiative remains at an exploratory stage.